Retraction notices

Certolizumab pegol demonstrates efficacy in maintaining response and remission in patients with active Crohn’s disease regardless of their immunosuppressant treatment status at entry to the PRECiSE 2 study

Type

Expression of concern

Notice date

1/24/2022 0:00

Journal

Journal of Crohn's and Colitis

Publisher

Oxford University Press

Notice DOI

10.1093/ecco-jcc/jjab227

Original paper DOI

10.1016/s1873-9946(10)00006-1

Reasons

• Civil Proceedings
• Concerns/Issues about Data
• Concerns/Issues about Results and/or Conclusions
• Legal Reasons and/or Threats